Colliers International Group shares jumped in pre-market trading after the real estate services firm reported second-quarter revenue and earnings that surpassed analyst expectations and maintained its full-year growth forecast.
According to a new HSBC analysis, investor concerns that major tech companies are overspending on AI capital expenditures have become the most probable narrative driving the market, with a 37% likelihood.
Shares of Sphere Entertainment gained in pre-market trading as the company prepared to release its second-quarter results, with investors betting on a performance that could surpass Wall Street's tempered expectations.
The laboratory operator boosted its annual earnings guidance after beating second-quarter estimates, but shares fell as growth in its core diagnostics unit slightly missed expectations.
Shares of the polymer products manufacturer declined after its second-quarter revenue fell significantly short of Wall Street expectations, overshadowing a strong beat on earnings per share.
Barclays has named L’Oréal and Unilever its top picks in the European consumer staples sector, citing resilient demand for premium beauty and superior innovation as key advantages in a slowing market.
Futures for Canada's main stock index pointed to a higher open on Thursday, buoyed by better-than-expected corporate results in the resources sector and elevated energy prices amid escalating tensions in the Middle East.
Alnylam Pharmaceuticals shares fell sharply after the company reported second-quarter revenue that missed estimates and significantly lowered its full-year sales forecast, citing slowing demand for a key drug.
Clinical-stage biopharmaceutical firm Braveheart Bio Inc. is seeking to raise up to $318.8 million in an initial public offering to advance its late-stage drug for hypertrophic cardiomyopathy, a common heart condition.
